1319 ET - Bicycle Therapeutics takes a beating after sharing its latest cancer treatment trial results. B. Riley analyst Kalpit Patel says the results for Bicycle's zelenectide pevedotin therapy in conjunction with Merck's pembrolizumab to treat bladder cancer included "a significant proportion of unconfirmed responses," and while the data are early, he says the effectiveness appears to be "somewhat underwhelming," when compared to the established combination of Astellas' Padcev + pembro. Patel also says results for Bicycle's breast and lung cancer treatment relied on a post-hoc analysis, which carries "an inherent risk of data mining." The analyst cautions that outcomes from such analyses often fail to replicate in later studies. Bicycle Therapeutics plunges 30% to $14.07. (katherine.hamilton@wsj.com)
(END) Dow Jones Newswires
December 13, 2024 13:19 ET (18:19 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.